A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease

PharmacoEconomics

Volumn 25, Issue 8, 2007, Pages 695-711

  Rutten van Mölken, Maureen P M H ^a   Van Nooten, Floortje E ^a   Lindemann, Marion ^b   Caeser, Manfred ^b   Calverley, Peter M A ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ALTANA PHARMA AG   (Germany)

^c University Hospital Aintree ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; PLACEBO; ROFLUMILAST; SALBUTAMOL;

ABSENTEEISM; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PRODUCTIVITY; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

AGED; AMINOPYRIDINES; BENZAMIDES; COST-BENEFIT ANALYSIS; CYCLOPROPANES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 34547191725     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725080-00007     Document Type: Article

References (49)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932-46
2. Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21 (2): 347-60
3. Vermeire P. The burden of chronic obstructive pulmonary disease. Respir Med 2002; 96 Suppl. C: S3-10
4. GOLD: Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. Bethesda (MD): National Institutes of Health, National Heart, Lung and Blood Institute, 2005
5. Feenstra TL, van Genugten ML, Hoogenveen RT, et al. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 2001; 164 (4): 590-6
6. Hoogendoorn M, Rutten-van Mölken MPMH, Hoogenveen RT, et al. A dynamic population model of disease progression in COPD. Eur Respir J 2005; 26 (2): 223-33
7. Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19 (6): 623-42
8. Oostenbrink JB, Rutten-van Mölken MPMH. Resource use and risk factors in high cost exacerbations of COPD. Respir Med 2004; 98: 883-91
9. Pauwels R, Löfdahl C-G, Pride N, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340 (25): 1948-53
10. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 819-23
11. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303
12. LHSRG: Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9
13. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease. A randomised controlled trial. Lancet 2005; 366 (9485): 563-71
14. Fabbri LM, Sanchez-Toril F, McIvor RA, et al. Effect of roflumilast on exacerbations: a 1-year study in patients with severe to very severe COPD [abstract]. Proc Am Thorac Soc 2006; 3: A 841
15. Calverley PM, Sanchez-Toril F, McIvor RA, et al. Effect of roflumilast on lung function: a 1-year study in patients with severe to very severe COPD [abstract]. Proc Am Thorac Soc 2006; 3: A 725
16. ATS: American Thoracic Society. Standardisation of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-36
17. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation: the St George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-7
18. NHS Executive. NHS reference costs, 2003. Leeds: NHS, 2003 [online]. Available from URL: http://www.dh.gov.uk/en/Policyandguidance/Organisation policy/Financeandplanning/NHSreferencecosts/index.htm [Accessed 2005 Apr 15]
19. Curtis L, Netten A. Unit costs of health & social care 2004. Canterbury: Personal Social Services Research Unit, University of Kent, 2004 [online]. Available from URL: http://www.pssru.ac.uk/uc/uc2004.htm [Accessed 2005 Apr 15]
20. NHS Executive. NHS returns, 2003/2004. Leeds, NHS [online]. Available from URL: http://www.dh.gov.uk/en/Publication.sandstatistics/Statistics/index. htm [Accessed 2005 Apr 15]
21. Office of National Statistics. National statistics online [online]. Available from URL: http://www.statistics.gov.uk/CCI/nugget.asp?ID=19 [Accessed 2005 Apr 15]
22. European Central Bank. Euro foreign exchange reference rates [online]. Available from URL: http://www.ecb.int/stats/eurofxref/ [Accessed 2005 Apr 15]
23. Office of National Statistics. Labour force survey: historical quarterly supplement. [online] Available from URL: http://www.statistics.gov.uk/STATBASE/ Source.asp?vlnk=358&More=Y [Accessed 2005 Apr 15]
24. Koopmanschap MA, Rutten FFH, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171-89
25. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, et al. Handleiding voor kostenonderzoek; methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Diemen: College voor zorgverzekeringen, Geactualiseerde versie, 2004
26. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19 (3): 398-404
27. Rubin DB. Multiple imputation for nonresponse in surveys. 1st ed. New York: J. Wiley and Sons, 1987
28. Rubin DB, Schenker N. Multiple imputation in healthcare databases: an overview and some applications. Stat Med 1991; 10: 595-8
29. Schafer J. Analysis of incomplete multivariate data. 1st ed. London: Chapman and Hall, 1997
30. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327-40
31. Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc 1996; 91: 473-89
32. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification in the propensity score. J Am Stat Assoc 1984; 79: 516-24
33. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and c/e-ratios alongside a clinical trial. Health Econ 1994; 3: 309-19
34. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Econ 2004; 13 (5): 405-15
35. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9 (7): 623-30
36. Decramer M, Gosselink R, Rutten-van Mölken MPMH, et al. Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax 2005; 60: 335-42
37. Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ 2005; 14 (8): 763-76
38. Lin D, Feuer E, Etzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics 1997; 53: 419-34
39. Oostenbrink JB, Rutten-van Mölken MPMH, Al MJ, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 241-9
40. Briggs AH, Lozano-Ortega G, Spencer S, et al. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value Health 2006; 9 (4): 227-35
41. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004; 116 (5): 325-31
42. Löfdahl CG, Ericsson A, Svensson K, et al. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics 2005; 23 (4): 365-75
43. Calverley PMA, Celli BR, Anderson JA, et al. The TORCH (Towards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years [abstract no. E311]. Eur Respir J 2006; 28: S50
44. Drummond MF, Pang F. Transferability of economic evaluation results. In: Drummond MF, McGuire A, editors. Economic evaluation in health care: merging theory with practice. 1st ed. Oxford: Oxford University Press, 2001
45. Pang F. Design, analysis and presentation of multinational economic studies: the need for guidance. Pharmacoeconomics 2002; 20 (2): 75-90
46. Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 2004; 8 (49): iii-iv, 1-192
47. Willke RJ, Glick HA, Polsky D, et al. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7: 481-93
48. Grieve R, Nixon R, Thompson SG, et al. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Econ 2005; 14 (2): 185-96
49. Manca A, Rice N, Sculpher MJ, et al. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ 2005; 14 (5): 471-85